Neutrophil to lymphocyte ratio as a prognostic marker for non-metastatic renal cell carcinoma — does it add to what we already know?

Authors

  • S. Rawoot P. D. Hinduja Hospital and Medical Research Centre
  • C. Punatar P. D. Hinduja Hospital and Medical Research Centre
  • V. Singh P. D. Hinduja Hospital and Medical Research Centre
  • A. Anand P. D. Hinduja Hospital and Medical Research Centre
  • B. Shah P. D. Hinduja Hospital and Medical Research Centre
  • S. Nagaonkar P. D. Hinduja Hospital and Medical Research Centre
  • V. Joshi P. D. Hinduja Hospital and Medical Research Centre

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-3.16543

Keywords:

neutrophil to lymphocyte ratio, prognostic factors, renal cell carcinoma

Abstract

Summary. Aim: To study the correlation of pre-operative neutrophil to lymphocyte ratio (NLR) with pathological stage, Fuhrman grade, sarcomatoid differentiation, tumor necrosis and lymph node positivity and its prognostic role in non-metastatic renal cell carcinoma (non-mRCC). Materials and Methods: This retro-prospective, observational study was done at a tertiary care center in Mumbai, India. All patients with non-mRCC from July 2015 to April 2018 were included. Patients with co-existing systemic infection, prior immunotherapy, and long-term steroids were excluded. NLR closest to surgery, but within one month prior to surgery was used. Patients were stratified as NLR ≥ 3.0 or < 3. NLR was correlated with known prognostic factors by Pearson’s correlation. Results: 113 patients, aged 18–81 years (83 males and 30 females) were included. 75% had clear cell RCC. 62% had stage 1 disease. 58% patients had Fuhrman Grade 2. 10 patients had lymph node metastasis, 6 had sarcomatoid differentiation, 40 had tumor necrosis. The NLR was < 3 in 72 patients. Statistically significant correlation between NLR and tumor stage (p = 0.0054) as well as NLR and tumor necrosis (p = 0.0128) was shown. Conclusions: NLR correlates significantly with higher T stage and tumor necrosis. NLR may be integrated with well-established prognostic markers to improve the accuracy of prognostic scores.

References

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30. https://doi.org/10.3322/caac.21166.

Singapore Cancer Registry report no. 7 2017; https://www.nrdo.gov.sg/docs/librariesprovider3/Publications-Cancer/inc_report_v745ce06a5c9d76bafab5aff000014cdee. pdf?sfvrsn=0.

Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 2013; 108: 901–7. https://doi.org/10.1038/bjc.2013.28.

Ljungberg B, Bensalah K, Canfield S, et al. EAU Guidelines on Renal Cell Carcinoma: 2014 Update. Eur Urol 2015; 67: 913–24. https://doi.org/10.1016/j.eururo.2015.01.005.

Meskawi M, Sun M, Trinh Q-D, et al. A Review of integrated staging systems for renal cell carcinoma. Eur Urol 2012; 62: 303–14. https://doi.org/10.1016/j.eururo.2012.04.049.

Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer 2003; 97: 1663–71. https://doi.org/10.1002/cncr.11234.

Roxburgh CSD, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Futur Oncol 2010; 6: 149–63. https://doi.org/10.2217/fon.09.136.

Hu K, Lou L, Ye J, Zhang S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ Open 2015; 5: e006404. https://doi.org/10.1136/bmjopen- 2014-006404.

Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009; 58: 15–23. https://doi.org/10.1007/s00262-008-0516-3.

Ohno Y, Nakashima J, Ohori M, et al. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 2010; 184: 873–8. https://doi.org/10.1016/j.juro.2010.05.028.

Viers BR, Houston TR, Boorjian SA, et al. Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urol Oncol Semin Orig Investig 2014; 32: 1277–84. https://doi.org/10.1016/j.urolonc.2014.05.014.

Otunctemur A, Dursun M, Besiroglu H, et al. Clinical significance of preoperative neutrophil — to — lymphocyte ratio in renal cell carcinoma. Int Braz J Urol 2016; 42: 678–84. https://doi.org/10.1590/S1677-5538.IBJU.2015.0397

Jagdev SPK, Gregory W, Vasudev NS, et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 2010; 103: 1649–56. https://doi.org/10.1038/sj.bjc.6605973

Wen RM, Zhang YJ, Ma S, et al. Preoperative neutrophil to lymphocyte ratio as a prognostic factor in patients with non-metastatic renal cell carcinoma. As Pac J Cancer Prev 2015; 16: 3703–8. https://doi.org/10.7314/apjcp.2015.16.9.3703.

Byun SS, Hwang EC, Kang SH, et al. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in nonmetastatic renal cell carcinoma: A large, multicenter cohort analysis. Biomed Res Int 2016; 2016: 5634148. https://doi.org/10.1155/2016/5634148. https://doi.org/10.1155/2016/5634148.

de Martino M, Pantuck AJ, Hofbauer S, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol 2013; 190: 1999–2004. https://doi.org/10.1016/j.juro.2013.06.082.

Downloads

Published

26.05.2023

How to Cite

Rawoot, S., Punatar, C., Singh, V., Anand, A., Shah, B., Nagaonkar, S., & Joshi, V. (2023). Neutrophil to lymphocyte ratio as a prognostic marker for non-metastatic renal cell carcinoma — does it add to what we already know?. Experimental Oncology, 43(3), 247–251. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-3.16543

Issue

Section

Original contributions